United Therapeutics Explores Pig Heart Transplants And Space Labs As Valuation Lags

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.

United Therapeutics (NasdaqGS:UTHR) received FDA clearance for a first-of-its-kind clinical study to transplant gene-edited pig hearts, known as UHeart, into human patients with end-stage heart failure. The company is also working with Varda Space Industries on microgravity-based drug formulation to support new approaches to treating pulmonary diseases.

United Therapeutics focuses on therapies for serious cardiopulmonary conditions, and these two projects put the company at the intersection of advanced transplantation science and space-assisted drug development. For investors tracking healthcare, these initiatives sit alongside broader efforts across the industry to address organ shortages and refine complex biologic and inhaled therapies.

For your watchlist, the key questions now revolve around clinical progress for UHeart and what, if anything, space-based manufacturing adds to United Therapeutics' formulation capabilities over time. Both programs are still early, so upcoming scientific updates, regulatory feedback, and partnering activity may be important reference points for anyone following NasdaqGS:UTHR.

Stay updated on the most important news stories for United Therapeutics by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on United Therapeutics.NasdaqGS:UTHR Earnings & Revenue Growth as at May 2026

We've flagged 0 risks for United Therapeutics. See which could impact your investment.

Quick Assessment

✅ Price vs Analyst Target: The current price of US$565.87 sits about 15% below the US$665.23 analyst target, with estimates ranging from US$516 to US$750. ✅ Simply Wall St Valuation: Shares are described as trading about 69.8% below an estimated fair value, flagging a sizable valuation gap. ❌ Recent Momentum: The stock is down 1.3% over the past 30 days despite the positive trial clearance and space collaboration headlines.

There is only one way to know the right time to buy, sell or hold United Therapeutics. Head to Simply Wall St's company report for the latest analysis of United Therapeutics's Fair Value.

Key Considerations

📊 UHeart and the Varda microgravity program both extend United Therapeutics' reach in high science areas tied to organ scarcity and complex pulmonary treatments. 📊 Watch clinical milestones for UHeart, regulatory feedback, and any disclosure on how space based work feeds into pipelines or partnerships. ⚠️ The UHeart trial introduces scientific, regulatory, and bioethical uncertainty that could affect timelines or public perception if outcomes disappoint.

Story Continues

Dig Deeper

For the full picture including more risks and rewards, check out the complete United Therapeutics analysis. Alternatively, you can check out the community page for United Therapeutics to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include UTHR.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments